Aequs sets EGM for Oct 22 to approve ₹650 crore warrant issue
- Aequs Ltd schedules EGM for October 22, 2026, to approve ₹650 crore warrant issue
- Warrants issued to promoter group entity Mellwood Trustee Services at ₹231.55 each
- Remote e-voting opens October 19, 2026, with cut-off date October 15, 2026
- Promoter shareholding expected to rise from 59.09% to 60.73% upon full conversion

*this image is generated using AI for illustrative purposes only.
Aequs Limited has finalized the schedule for its Extra-Ordinary General Meeting (EGM) on October 22, 2026, to seek shareholder approval for a ₹650 crore preferential issue of warrants convertible into equity shares. The meeting will be held via video conferencing at 4:30 pm.
The warrants will be issued to Mellwood Trustee Services Private Limited (Trustee of the Melligeri Private Family Foundation), a member of the Promoter Group. The proposal was approved by the Board on September 25, 2026. Shareholders can cast their votes electronically from October 19, 2026, to October 21, 2026.
Issue Structure and Pricing
The Board approved the preferential issue of up to 2,80,71,690 warrants, each convertible into one fully paid-up equity share of face value ₹10. The issue price is set at ₹231.55, determined as the floor price under Regulation 164 of the SEBI ICDR Regulations. This price represents the higher of the 90-trading-day and 10-trading-day volume weighted average price preceding September 22, 2026.
| Parameter | Details |
|---|---|
| Total Issue Size | ₹650 crore |
| Number of Warrants | 2,80,71,690 |
| Face Value | ₹10 per share |
| Issue Price | ₹231.55 per warrant |
| Upfront Payment | ₹325 crore (50%) |
| Conversion Deadline | December 31, 2027 |
Utilization of Funds
The proceeds from the warrant issue are earmarked for expanding capacities in two key sectors:
- Aerospace components manufacturing
- Consumer goods production capabilities
The funds will specifically support the development of the Hosur facility, investments in subsidiaries and joint ventures supporting expansion, and general corporate purposes. The equity infusion will also provide the base against which the Company raises term borrowings for these projects. The immediate receipt of 50% of the funds allows the company to commence these expansion projects without waiting for the full tranche completion.
Promoter Commitment and Shareholding
Of the total issue size, ₹325 crore will be payable upfront upon allotment, representing 50% of the issue size and twice the regulatory minimum. The balance consideration is payable upon exercise of the warrants, which must occur within 18 months from allotment. However, conversion into equity shares must take place on or before December 31, 2027. The Promoter has undertaken to pay the balance consideration in full, irrespective of the market price at the time of exercise.
Upon full conversion, the aggregate holding of the Promoter and Promoter Group in Aequs will increase from 59.09% to 60.73%.
Regulatory Compliance and Voting Details
The intimation regarding the board approval was issued pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ravi Mallikarjun Hugar, Company Secretary and Compliance Officer, signed the disclosure filed with the National Stock Exchange of India Limited and BSE Limited.
The company has provided facilities for remote e-voting and e-voting at the EGM. The remote e-voting period commences on Monday, October 19, 2026, at 9:00 am and ends on Wednesday, October 21, 2026, at 5:00 pm. Members holding shares as on the cut-off date of October 15, 2026, are entitled to vote.
Historical Stock Returns for Aequs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.60% | -7.10% | +16.96% | +83.58% | +74.70% | +74.70% |
How will the expansion of aerospace and consumer goods capacities at the Hosur facility impact Aequs's revenue mix and profit margins in the next fiscal year?
What specific term borrowing plans is Aequs pursuing to leverage the ₹325 crore upfront equity infusion, and how will this affect its debt-to-equity ratio?
Given the fixed conversion price of ₹231.55, how might significant market price appreciation by the December 2027 deadline influence the promoter's willingness to exercise the warrants?


































